Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24687980 | 0.87 | TDP1 (0.50) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL361540 | 0.87 | TDP1 (0.50) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL31059571 | 0.87 | TDP1 (0.50) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL1127369 | 0.86 | CA1 (0.43) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL1127348 | 0.84 | CA1 (0.41) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL1127639 | 0.84 | CA1 (0.41) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL16569009 | 0.83 | CA1 (0.49) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL22404435 | 0.83 | CA1 (0.49) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL12493914 | 0.82 | TDP1 (0.53) | TDP1CA1CA2CA7CTSK | |
| SCHEMBL12493912 | 0.82 | TDP1 (0.53) | TDP1CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| EP-2282981-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| EP-2123620-A1 | {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | TDP1 4378/4885CA1 231/4885CA2 981/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | TDP1 4427/4885CA1 203/4885CA2 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.